论文部分内容阅读
目的:研究MiRNAs在乳腺癌患者血清中的异常表达及其作为潜在诊断标志物的临床价值。方法:选择乳腺癌患者作为观察组、乳腺良性疾病患者作为良性对照组、健康体检者作为健康对照组,检测外周血中miR-7b、miR-143、miR-145、miR 221和miR 223的含量。结果:观察组患者miR-7b、miR-143、miR-145含量明显低于良性对照组和健康对照组,呈现出TNMⅡ期>Ⅲ期>Ⅳ期、且与TNM分期呈负相关;miR-7b、miR143、miR-145、miR-221、miR-223的表达差异与雌、孕激素受体表达密切相关,其中miR-221、miR-223、miR-7b表现出显著相关性(P<0.05);miR-7b曲线下面积82.6%(95%CI:0.768~0.906),miR-221曲线面积93.24%(95%CI:0886~0.943),miR-223曲线下面积92.4%(95%CI:0.882~0.938)。结论:miR-7b、miR-143、miR-145、miR221和miR223在乳腺癌患者血清中表达异常,与病理分期、雌、孕激素受体表达量密切相关,其中miR-221、miR-223、miR-7b可作为潜在标志物,对乳腺癌的病理特征具有诊断价值。
Objective: To investigate the abnormal expression of MiRNAs in serum of breast cancer patients and its clinical value as a potential diagnostic marker. Methods: The patients with breast cancer were selected as the observation group and the benign breast disease patients as the benign control group. The healthy subjects were taken as healthy control group to detect the content of miR-7b, miR-143, miR-145, miR 221 and miR 223 in peripheral blood . Results: The levels of miR-7b, miR-143 and miR-145 in observation group were significantly lower than those in benign control group and healthy control group, showing TNMⅡ> III> Ⅳ, and negatively correlated with TNM staging; miR- The expression of miR-143, miR-145, miR-221 and miR-223 was closely related to the expression of estrogen and progesterone receptor, and miR-221, miR- ; the area under the curve of miR-7b was 82.6% (95% CI: 0.768-0.906), the area of miR-221 was 93.24% (95% CI: 0886-0.943) ~ 0.938). The expression of miR-7b, miR-143, miR-145, miR221 and miR223 in serum of breast cancer patients was abnormal, which was closely related to the pathological stage, estrogen and progesterone receptor expression. miR-7b can be used as a potential marker for the diagnosis of breast cancer pathological features.